We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Removing Tissue Surrounding Breast Cancer Tumors Prevents Residual Disease

By HospiMedica International staff writers
Posted on 01 Nov 2010
Removing an extra two millimeters around an area of invasive breast cancer is sufficient to minimize any residual disease in 98% of patients, according to a new study.

Researchers at Good Hope Hospital (Sutton Coldfield, United Kingdom) studied 303 women who had undergone breast-conserving surgery at the hospital between 2002 and 2008. More...
The researchers carried out further excision specimens on 31% of the women who had received breast-conserving surgery to check for residual disease, obtaining 139 samples from 93 patients. Of these, 52 samples were from patients who had received surgery for noninvasive cancer (tumor confined to the milk ducts or lobules), and 87 were from patients who had received treatment for invasive cancer that had spread to the surrounding breast tissue.

The researchers found that in the women who had received surgery for invasive cancer, the amount of residual disease, defined as the presence of invasive or noninvasive cancer, reduced as the free margin increased – from 35.3% with no margin to 2.4% with a margin of more than two mm. However, when it came to the women who had received surgery for noninvasive cancer, residual disease was higher and the pattern was less than clear. Incidence ranged from 0% at more than 5 mm to 57% when the margin was between 0.1 mm to 0.9 mm, but at 44% where no margin was involved.

The researchers also looked at the characteristics of the 202 women who had had a close free margin of less than two mm and the 101 women who had had a clear free margin of two mm or more.

They found that women with a close margin of less than two mm were more likely to be associated with large grade three tumors than the clear margin group (46% vs. 42%), lymphovascular invasion (52% vs. 40%), and nodal involvement (48% vs. 33%). In addition to the women who underwent wider reexcision to determine any residual disease, 13% went on to have a mastectomy, and the remaining 56% did not have further surgery. The study was published in the November 2010 issue of the International Journal of Clinical Practice.

"Based on these results, we feel confident that a free margin of two mm from the area of invasive cancer is adequate to minimize residual disease, but the equivalent free margin for noninvasive cancer remains unclear,” concluded lead author Stephen Ward, M.D., and colleagues of the department of breast surgery. "Eliminating the possibility of residual disease during breast conserving surgery is very important as nearly 50% of patients with local recurrence go on to develop secondary breast cancer, which is a progressive incurable disease.”

Related Links:

Good Hope Hospital




Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Electric Bed
DIXION Intensive Care Bed
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.